[EN] BENZAZEPIN-L,7-DIOL-DERIVED RADIOLABELED LIGANDS WITH HIGH IN VIVO NMDA SPECIFICITY<br/>[FR] LIGANDS RADIOMARQUÉS DÉRIVÉS DE BENZAZÉPIN-L,7-DIOL PRÉSENTANT UNE SPÉCIFICITÉ DE NMDA IN VIVO ÉLEVÉE
申请人:ETH ZUERICH
公开号:WO2020099537A1
公开(公告)日:2020-05-22
The present invention is directed to benzazepin-1,7-diol-derived compounds (I) for use in the diagnosis of NMDA (N-methyl-D-aspartate) receptor-associated diseases or disorders by positron emission tomography (PET), single-photon emission computed tomography (SPECT), liquid based-scintillation- and/or autoradiography-based assays. The invention also relates to a method for the diagnosis of NMDA receptor-associated diseases or disorders by administering to a patient or a sample of a patient in need of such diagnosis a compound of the invention in an amount effective for PET imaging, SPECT imaging, liquid based-scintillation- and/or autoradiography-based assays of NMDA receptors, recording at least one PET or SPECT scan, liquid based-scintillation or autoradiography result, and diagnosing an NMDA receptor-associated disease or disorder from an abnormal NMDA receptor expression pattern on the PET or SPECT scan, in the liquid based-scintillation or autoradiography result. The present invention also provides a method for evaluating a putative NMDA-receptor antagonist in a liquid scintigraphy detection assay or an autoradiography assay using the compounds of the present invention.
本发明涉及一类以苯并氮杂环庚烷-1,7-二醇为衍生物的化合物(I),用于通过正电子发射断层扫描(PET)、单光子发射计算机断层扫描(SPECT)、基于液体闪烁或放射自显影的检测方法,用于诊断NMDA(N-甲基-D-天冬氨酸)受体相关疾病或障碍。该发明还涉及一种诊断NMDA受体相关疾病或障碍的方法,通过向需要进行PET成像、SPECT成像、基于液体闪烁或放射自显影的NMDA受体检测的患者或患者样本中施用本发明的化合物,以有效剂量进行PET成像、SPECT成像、基于液体闪烁或放射自显影的NMDA受体检测,记录至少一次PET或SPECT扫描、基于液体闪烁或放射自显影的结果,根据PET或SPECT扫描中的异常NMDA受体表达模式、基于液体闪烁或放射自显影的结果诊断NMDA受体相关疾病或障碍。本发明还提供了一种使用本发明化合物进行液体闪烁检测或放射自显影检测的方法,用于评估假定的NMDA受体拮抗剂。